To include your compound in the COVID-19 Resource Center, submit it here.

Clinical cash

Hookipa shifts focus to clinical programs with €50M series C

Hookipa Biotech AG plans to use its €50 million ($59.4 million) series C round almost exclusively on its clinical development programs, and aims for the financing to be the company’s last before going public.

Hookipa plans to announce the round on

Read the full 415 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE